Jump to ContentJump to Main Navigation

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Editorial Board Member: Darendeliler, Feyza / Gustafsson, Jan / Luo, Feihong / Mericq, Veronica / Lanes M. D., Roberto / Battelino, Tadej / Buyukgebiz, Atilla / Cassorla, Fernando / Chrousos, George P. / Cutfield, Wayne / Fideleff, Hugo L. / Hershkovitz, Eli / LaFranchi, Stephen H. / Mohn, Angelika / Root, Allen W. / Rosenfeld, Ron G. / Wabitsch, Martin / Werther, George / Zadik, Zvi

6 Issues per year


IMPACT FACTOR increased in 2014: 0.995

SCImago Journal Rank (SJR) 2014: 0.378
Source Normalized Impact per Paper (SNIP) 2014: 0.454
Impact per Publication (IPP) 2014: 0.880

VolumeIssuePage

Issues

Evaluation of bone density in girls with precocious and early puberty during treatment with GnRH agonist

1 / Mordechai Weiss2 / Dorit Aharoni3 / Anat Mor3 / Mariana Rachmiel4 / Tzvi Bistritzer4

1Pediatric Division, Assaf Harofeh Medical Center, Zerifin, Affiliated to Sackler School of Medicine, Tel-Aviv, Israel

2Endocrinology Unit, Assaf Harofeh Medical Center, Zerifin, Affiliated to Sackler School of Medicine, Tel-Aviv, Israel

3Biochemical Laboratory, Assaf Harofeh Medical Center, Zerifin, Affiliated to Sackler School of Medicine, Tel-Aviv, Israel

4Pediatric Endocrinology Unit, Assaf Harofeh Medical Center, Zerifin, Affiliated to Sackler School of Medicine, Tel-Aviv, Israel

Corresponding author: Amit Assa, MD, Pediatric Division, Assaf Harofeh Medical Center, Zerifin 70300, Israel Phone: +972-8-9779133, Fax: +972-8-9779136

Citation Information: Journal of Pediatric Endocrinology and Metabolism. Volume 24, Issue 7-8, Pages 505–510, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: 10.1515/jpem.2011.170, June 2011

Publication History

Published Online:
2011-06-17

Abstract

Background: Major changes in bone status occur during puberty. Most longitudinal studies have shown no impairment in bone mineral density (BMD) in girls with precocious (PP) and early puberty (EP) during and after GnRH agonist therapy.

Methods: In the present study we evaluated BMD, bone strength (BS) and bone metabolism in 26 girls with PP and with EP before and during treatment with GnRH agonist. BMD was measured by dual energy X-ray absorptiometry and BS was measured using the quantitative high frequency ultrasound technique at baseline, after 6 and 12 months from onset of therapy. Variables were compared with age- and sex-matched values of the same population. Biochemical markers of bone turnover were measured at the same intervals.

Results: Mean lumbar spine (LS) and femoral neck (FN) BMD were significantly lower at baseline (LS: p<0.0001, FN: p<0.0017) compared with age-matched reference values. Bone strength was significantly lower at the radius (p<0.0001) and normal at the tibia. A non-significant increase in BMD and a significant increase in BS were observed throughout the first year of therapy with GnRH agonist. Serum bone specific alkaline phosphatase measurements were normal at baseline and remained stable. Urinary deoxypyridinoline\creatinine measurements were significantly higher (p<0.0001) at baseline and decreased significantly (p<0.001) during treatment.

Conclusions: Girls with central idiopathic PP and EP have lower BMD and BS for chronological age and increased bone resorption markers. These parameters show a trend of normalization during the first year of therapy with GnRH agonist.

Keywords: bone mineral density; dual X-ray absorptiometry; early puberty; precocious puberty; quantitative ultrasound

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
László Ságodi, Enikő Sólyom, Béla Lombay, Andrea Almási, and Ildikó Vámosi
Orvosi Hetilap, 2012, Volume 153, Number 11, Page 418

Comments (0)

Please log in or register to comment.